Vaxcyte shares are trading higher after B of A Securities maintained a Buy rating on the stock and raised its price target from $101 to $140.
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte shares rose following B of A Securities' decision to maintain a Buy rating and increase the price target from $101 to $140.
September 04, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxcyte's stock price increased after B of A Securities reaffirmed its Buy rating and raised the price target to $140, indicating strong confidence in the company's future performance.
The increase in price target from $101 to $140 by a major financial institution like B of A Securities is a strong positive signal for investors, suggesting expected growth and potential upside in Vaxcyte's stock. This is likely to attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100